|
16th June,
2009
Diabetology Limited Nominated as
One of 15 Most Innovative Healthcare Businesses by the HiT World
Innovation Summit 2009
Diabetology Limited is pleased to announce that it has
been nominated as one of the 15 most innovative healthcare
businesses by the HiT World Innovation Summit 2009.
The upcoming HiT World Innovation Summit (which will be
held in Barcelona on the 17th-19th June) has
focused on three global industries with exceptional growth potential
- healthcare, telecom and cleantech - and across these industries
they have selected 15 of the most innovative healthcare companies, of
which Diabetology is one of them.
Through its nomination Diabetology has been invited to
give a presentation and will be given an exhibition stand at the
conference. The presentation will be given on 18th
June in the session starting at 11:30.
Selection has also brought with it:
·
Free of charge office space in
Barcelona for 12 months
·
Potential to qualify for the 2009
European Venture Summit
·
Potential to be shortlisted for the
2009 European Venture Contest, with a €90,000 prize
NOTES TO EDITORS
About Diabetology Limited
Diabetology is a specialty biopharmaceutical company
employing a proprietary oral delivery system to administer known
bioactives as well as novel compounds for the comprehensive
management of diabetes.
Diabetology's
lead project is Capsulin, an oral encapsulated formulation of
recombinant human insulin for the treatment of patients with type 1
and type 2 diabetes. Diabetology intends to develop Capsulin both as
a novel oral anti-diabetic agent for the treatment of patients with
type 2 diabetes (Capsulin OAD) and as a replacement to injectable
insulin for patients suffering from type 1 and type 2 diabetes
(Capsulin IR).
The
company’s innovative drug delivery technology, Axcess™ Oral Drug
Delivery System, significantly increases the absorption of peptides,
proteins and other macromolecules across the intestinal wall when
delivered orally without any chemical modification of the active
compounds. It is based on a simple mixture of components
consisting entirely of registered pharmacopoeial or GRAS excipients
with a long history of pharmaceutical use. The absorption enhancing
activities obtained from the formulation of these excipients is
entirely novel and forms the basis of five international patent
applications. Diabetology has licensed exclusive rights to
Axcess™ for the formulation of oral therapies for diabetes.
About
HiT Barcelona World Innovation Summit 2009
HiT Barcelona
is a unique global event bringing together leading innovators,
experts, entrepreneurs and investors to share and expand knowledge
and to promote strategic business projects via tournaments. Focused
on three key sectors with a high growth potential, Telecom, CleanTech
and Healthcare, HiT Barcelona combines top-level plenary sessions
(Plenary Congress) with a programme of meetings and sector-specific
competitions of some of the most innovative business projects
worldwide (Innovation Marketplaces). The event will also host the
first ever truly international “Business-Plan/Early-Stage”
competition for entrepreneurs, the Global Entrepreneurship
Competition.
HiT
Barcelona is an initiative of the Spanish Ministry of Industry,
Commerce and Tourism, the Autonomous Government of Catalonia, the
Barcelona City Council (via their Finance, Economy and Innovation
Departments), the Barcelona Chamber of Commerce and La Caixa.
It is organised by the Fira de Barcelona and the Barcelona Plà
Estrategic. The first edition of the event is expected to bring to
Barcelona over 2,500 delegates from the 17th to the 19th of June
2009.
ENDS
For more information
contact:
Timothy P. Broke-Smith
Corporate Development Officer
Diabetology Limited
Tel: +44 (0)20 7193 8363
Email: t.broke-smith@diabetology.co.uk
|
